City of Hope Statistics

City of Hope is a cancer and diabetes research and treatment facility funded by charitable groups, such as the National Insurance Industry Council.

The Duarte, Calif.-based facility has some impressive accolades. Here are a few:

In 2014 City of Hope was awarded more than $72.9 million in research grants and received roughly $249.8 million in revenues from patented technologies.

Numerous breakthrough cancer drugs, including Herceptin, Rituxan and Avastin, are based on technology pioneered by City of Hope.

Millions of people with diabetes benefit from synthetic human insulin, developed through City of Hope research.

The facility was a pioneer in bone marrow and stem cell transplants, and has performed more than 12,000 such transplants.

Surgeons at City of Hope have performed more than 10,000 robotic procedures for prostate, kidney, colon, liver, bladder, gynecologic, oral and other cancers.

City of Hope holds more than 300 patents, and submits nearly 30 applications per year to the Food and Drug Administration for investigational new therapies.

Scientists at the facility pioneered the application of blood stem cell transplants to treat patients with HIV- and AIDS-related lymphoma. Researchers there used a new form of gene therapy to achieve the first long-term persistence of anti-HIV genes in patients with AIDS-related lymphoma. This treatment ultimately may cure not only lymphoma, but also HIV/AIDS, and researchers are expanding their studies with a new clinical trial.

Source: City of Hope